683 Capital Management’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

683 Capital Management’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-599,702	Closed	-$7.86K	–	255
2024 Q3	$7.86K	Hold	599,702	–	–	﹤0.01%	128
2024 Q2	$25.2K	Sell	599,702 -298	-0%	-$19	﹤0.01%	120
2024 Q1	$31.2K	Hold	600,000	–	–	﹤0.01%	110
2023 Q4	$30K	Hold	600,000	–	–	﹤0.01%	228
2023 Q3	$132K	Hold	600,000	–	–	0.01%	110
2023 Q2	$78K	Hold	600,000	–	–	0.01%	119
2023 Q1	$24.6K	Hold	600,000	–	–	﹤0.01%	251
2022 Q4	$30K	Hold	600,000	–	–	﹤0.01%	244
2022 Q3	$33K	Hold	600,000	–	–	﹤0.01%	180
2022 Q2	$54K	Hold	600,000	–	–	﹤0.01%	200
2022 Q1	$216K	Buy	600,000 +500,000	+500%	+$220K	0.01%	264
2021 Q4	$51K	Buy	+100,000	New	+$56.4K	﹤0.01%	317

Other funds holding CLDI.WS

EAM

Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return

683 Capital Management's CLDI.WS Position: Q4 2024 in Review

683 Capital Management sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q4 2024, closing a stake of 599,702 shares — an estimated $7.86K sold.

683 Capital Management first reported a position in CLDI.WS in Q4 2021 and held it in 12 quarters. The position peaked at $216K in Q1 2022. 1 fund tracked by Wall St. Rank holds CLDI.WS as of Q4 2024.

683 Capital Management reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q4 2024 after selling out during the quarter.
683 Capital Management sold 599,702 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q4 2024, an estimated $7.86K.
683 Capital Management first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q4 2021 and held it in 12 quarters.
683 Capital Management's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $216K in Q1 2022.
1 fund tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q4 2024.

Based on 683 Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.